Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
NEWARK, Calif., Sept. 18, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference, and the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology conference.
| Cantor Fitzgerald Global Healthcare Conference | ||
| Date: | Tuesday, September 26 | |
| Time: | 9:45am Eastern Time | |
| Location: | InterContinental New York Barclay Hotel | |
| Webcast: | http://ir.cymabay.com/events | |
| LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology | ||
| Date: | Wednesday, September 27 | |
| Time: | 3:00pm Eastern Time | |
| Location: | Lotte New York Palace Hotel | |
| Webcast: | http://ir.cymabay.com/events | |
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent and selective agonist of PPARδ, a nuclear receptor that regulates genes involved in bile acid/sterol, lipid and glucose metabolism and inflammation. Seladelpar is currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
